Abstract | BACKGROUND: Antiplatelet therapy ( APT) is generally used in patients with coronary artery disease. However, for patients with vasospastic angina (VSA), the impact of APT is not fully understood. METHODS: RESULTS: In the whole population, 669 patients received APT, while 760 patients did not receive APT. Patients with APT had a greater prevalence of comorbidities, such as hypertension, diabetes, dyslipidemia and smoking, than those without APT. The prevalences of previous myocardial infarction, spontaneous ST changes, significant organic stenosis and medications including calcium channel blocker, nitrate, statin and angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker were greater in patients with APT than those without APT. After propensity matching (n = 335 for both groups), during the median follow-up period of 32 months, the incidence rate of MACE was comparable between the patients with and without APT (P = 0.24). MACEs occurred in 5.7% of patients with APT and in 3.6% of those without APT (P = 0.20). All-cause death occurred in 0.6% of patients with APT and 1.8% of those without APT (p = 0.16). CONCLUSION: In this multicenter registry study, anti-platelet therapy exerted no beneficial effects for VSA patients.
|
Authors | Hiroyoshi Mori, Jun Takahashi, Koichi Sato, Satoshi Miyata, Yusuke Takagi, Ryusuke Tsunoda, Tetsuya Sumiyoshi, Motoyuki Matsui, Yasuhiko Tanabe, Shozo Sueda, Shinichi Momomura, Koichi Kaikita, Satoshi Yasuda, Hisao Ogawa, Hiroaki Shimokawa, Hiroshi Suzuki, Japanese Coronary Spasm Association |
Journal | International journal of cardiology. Heart & vasculature
(Int J Cardiol Heart Vasc)
Vol. 29
Pg. 100561
(Aug 2020)
ISSN: 2352-9067 [Print] Ireland |
PMID | 32551361
(Publication Type: Journal Article)
|
Copyright | © 2020 The Authors. Published by Elsevier B.V. |